Acumen Pharmaceuticals (ABOS) Stock Overview
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ABOS Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Acumen Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.24 |
| 52 Week High | US$3.60 |
| 52 Week Low | US$1.05 |
| Beta | 0.35 |
| 1 Month Change | -12.84% |
| 3 Month Change | -32.12% |
| 1 Year Change | 96.49% |
| 3 Year Change | -62.10% |
| 5 Year Change | n/a |
| Change since IPO | -88.86% |
Recent News & Updates
Oligomer Antibody And EBD Platform Will Reshape Early Alzheimer’s Treatment Over Time
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biotechnology company developing a beta oligomer targeted antibody therapies for Alzheimer's disease. What are the underlying business or industry changes driving this perspective?
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?Recent updates
Oligomer Antibody And EBD Platform Will Reshape Early Alzheimer’s Treatment Over Time
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biotechnology company developing a beta oligomer targeted antibody therapies for Alzheimer's disease. What are the underlying business or industry changes driving this perspective?Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Catalysts About Acumen Pharmaceuticals Acumen Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing a beta oligomer targeted antibody therapies for Alzheimer’s disease. What are the underlying business or industry changes driving this perspective?Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Summary Acumen Pharmaceuticals develops treatments for Alzheimer's disease targeting toxic AβOs, with promising results for sabirnetug in phase 1 clinical trial Intercept-AD. The potential for early AD is approximately 7 million patients, positioning ABOS for significant market share if successful. Sabirnetug’s Phase 1 trial showed promising results, reducing brain amyloid plaques and supporting its mechanism of action for treating early Alzheimer's disease. Acumen Pharmaceuticals has a healthy cash runway, estimated at 3.5 years, and appears undervalued relative to its peers in the biotech sector. Despite the promising data, investing in ABOS is speculative due to the early stages of research and the potential long timeline to FDA approval. Read the full article on Seeking AlphaIs Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
The shares of microcap biotech Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) more than doubled in value on Wednesday after its rivals Biogen (BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced promising late-stage data for experimental Alzheimer's therapy, lecanemab. In the trial involving nearly 1,800 patients, the amyloid targeting monoclonal antibody cut the cognitive and functional decline in the early stage of Alzheimer's by 27%, compared to placebo, the companies announced late Tuesday. With data validating the amyloid hypothesis in Alzheimer's, developers with similar drugs in their pipeline surged in value. Acumen (ABOS) is advancing its only drug candidate, ACU193 for Alzheimer's, with topline data from a Phase 1 trial expected in H1 2023. ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, which, according to the company, are the most toxic and pathogenic form of amyloid-beta.Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
H.C. Wainwright has initiated Acumen Pharmaceuticals (NASDAQ:ABOS) with a buy rating saying the biopharma's early-stage Alzheimer's candidate, ACU193, has promise. The firm has a $15 price target (~207% return based on Wednesday's closing price). Unlike many other Alzheimer's therapies in development -- and marketed ones such as Biogen's (BIIB) Aduhelm (aducanumab) -- that target the removal of beta amyloid plaque from the brain, ACU193 works differently as a anti-amyloid-beta oligomer (AβO) monoclonal antibody. Analyst Andrew Fein noted that ACU193 "lacks the inflammatory effector functions of other [immunoglobulin] subclasses, thereby making it less prone to [amyloid-related imaging abnormalities], a major safety issue with current anti-[amyloid beta] therapies. Acumen (ABOS) said ACU193 prevents toxic AβOs from binding to dendritic spines and preserves neural function. The company added the candidate has the potential for disease slowing as well as cognitive improvement. The ongoing phase 1 trial is expected to enroll 62 subjects with mild cognitive impairment or mild dementia.We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholder Returns
| ABOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | -1.9% | -4.1% |
| 1Y | 96.5% | 23.6% | 20.6% |
Return vs Industry: ABOS exceeded the US Biotechs industry which returned 25% over the past year.
Return vs Market: ABOS exceeded the US Market which returned 22.3% over the past year.
Price Volatility
| ABOS volatility | |
|---|---|
| ABOS Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABOS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABOS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 61 | Dan O'Connell | acumenpharm.com |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease.
Acumen Pharmaceuticals, Inc. Fundamentals Summary
| ABOS fundamental statistics | |
|---|---|
| Market cap | US$158.18m |
| Earnings (TTM) | -US$113.28m |
| Revenue (TTM) | n/a |
Is ABOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$104.93m |
| Gross Profit | -US$104.93m |
| Other Expenses | US$8.34m |
| Earnings | -US$113.28m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 35.5% |
How did ABOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 18:44 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acumen Pharmaceuticals, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |